In August 2015, Bactiguard received a one off order from C.R. Bard (Bard), intended to increase their safety stock, which generated additional sales of approximately 28 MSEK in the third quarter. Bard has subsequently revised their need of safety stock. This adjustment will have a negative impact on Bactiguard’s revenues of approximately 8...
For the ninth year in a row Bactiguard is exhibiting at Arab Health, which is one of the world's largest conferences for the health care sector. The interest in preventive and anti-infective solutions for healthcare associated infections are growing explosively along with the global threat of multiresistant bacteria and antibiotic resistance....
Attorney Jan Lombach will replace Christian Kinch and has also been appointed chairman of the Nomination Committee. Following these changes, the Nomination Committee for the 2016 AGM in Bactiguard Holding AB (publ) will consists of the following members: Stanley Brodén, Chairman of the Board of Directors Jan Lombach, appointed by KK Invest AB,...
The planned multi-center clinical study in India has been initiated and the first patients recruited at two reputable hospitals. The purpose of the study is to further validate the efficiency and patient safety of Bactiguard’s Foley catheters in the prevention of catheter-related urinary tract infections. Healthcare associated infections are a...
Bactiguard has received a major order from India of some 50 000 Foleys for infection prevention. At the same time, the planned clinical study has been initiated. The first order from India consists of some 50 000 Foley catheters for infection protection (BIP Foleys) and generates direct sales revenues of close to 2 million SEK, at product...
Bactiguard has received an order from the Middle East, comprising 2 000 central venous catheters (BIP CVC) and 20 000 Foleys (BIP Foley). The delivery will take place before the end of the year. The Middle East is one of Bactiguard’s focus markets and continues to generate repeat orders, so far primarily of Foley catheters. There is a growing...
The Annual General Meeting in Bactiguard Holding AB (publ) will be held on Thursday 19 May, 2016 in Botkyrka. At the Annual General Meeting (AGM) in 2015, it was resolved that the Nomination Committee in Bactiguard Holding AB (publ) shall consist of four members. The chairman of the Board of Directors shall contact the three largest shareholders...
Third Quarter (July-September 2015) Revenues amounted to SEK 61.4 (28.1) million. The increase (118 %) compared to the corresponding quarter 2014 is mainly attributable to the additional order from C.R. Bard. EBITDA amounted to SEK 33.9 (2.2) million. Operating profit amounted to SEK 25.7 (-5.3) million. Reported net profit for the quarter...
Bactiguard and Vigilenz Medical Devices (Vigilenz), a Malaysian supplier of medical and surgical products, have entered into a license agreement for Bactiguard coated orthopaedic implants, covering the Asean region. Bactiguard aims to expand its licensing business to new therapeutic areas and Vigilenz’ ambition is to enhance its existing...
Bactiguard has entered a credit facility agreement of 130 million SEK in total. Combined with the company’s cash position, the credit facility secures the refinancing of Bactiguard’s bond loan, which matures in December 2016. During the autumn, Bactiguard has been working on securing the refinancing of its bond loan. The income received in...
Bactiguard Holding AB publishes the interim report for the third quarter on Thursday 12 November at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on November 12. CEO Christian Kinch and CFO Fredrik Järrsten will present the interim report and answer questions. The report and a...
Ulrika Berglund has been appointed Head of External Affairs at Bactiguard and will be responsible for communications and public affairs. She succeeds Cecilia Edström, who will assume an extended responsibility for sales and business development. “I am very pleased with the recruitment of Ulrika Berglund to Bactiguard. With her extensive media...
Two recent clinical studies, both independent and randomized, show that Bactiguard-coated Foley catheters and endotracheal tubes reduce catheter associated urinary tract infections and ventilator associated pneumonia. The first study was conducted in Spain and included 116 patients catheterized for 2 – 14 days, with a mean of 4 days, during the...
Second Quarter (April-June 2015) During the second quarter, a total of approx. 58,000 (44,000) BIP products were delivered. Revenues amounted to SEK 27.7 (31.2) million. EBITDA amounted to SEK -10.0 (2.2) million. Provisions for severance pay to the former CEO as well as for doubtful accounts receivable have negatively affected EBITDA during the...
Bactiguard has received a major, one off order from C.R. Bard (Bard) intended to increase their safety stock of Bactiguard-coated Foleys for infection control. The order will generate additional sales for Bactiguard of approximately 28 MSEK in the third quarter and make a positive contribution to cash flow. The additional order will lead to...
Bactiguard Holding AB publishes the interim report for the second quarter on Thursday 13 August at 8:00 CET In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on August 13. CEO Christian Kinch and CFO Fredrik Järrsten will present the interim report and answer questions. The report and a...
Bactiguard delivers an order of more than 20 000 Foley catheters for infection control to Saudi Arabia. At the end of June, Bactiguard delivered an order of more than 20 000 Foley catheters to Gulf Medical in Saudi Arabia. Gulf Medical distributes Bactiguard’s portfolio of products for infection control to the healthcare system in both Saudia...
Niels Christiansen leaves his position as CEO of Bactiguard Holding AB (publ) with immediate effect. The Board has appointed Christian Kinch, currently Chairman of the Board, as new CEO. Stanley Brodén has been appointed Chairman of the Board until the Annual General Meeting (AGM) in 2016. “The recruitment of Niels Christiansen as CEO was...
At Bactiguard Holding AB’s (publ) Annual General Meeting on May 21, the following resolutions were made: The Annual General Meeting adopted the income statement and balance sheet for 2014. It was decided that no dividend for the financial year 2014 will be paid and that the company's loss (for the year) will be carried forward. The Board of...
First quarter (January-March 2015) Revenues amounted to SEK 28.8 (34.5) million EBITDA amounted to SEK -26.8 (9.8) million. A changed market strategy for Russia and India has led to provisions for doubtful receivables. These provisions, together with non-recurring costs attributable to a strategic marketing project, have negatively affected EBITDA...
Bactiguard Holding AB publishes the interim report for the first quarter on Tuesday 12 May at 8:00 CET In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on May 12. CEO Niels Christiansen and CFO Fredrik Järrsten will present the interim report and answer questions. The report and a...
Bactiguard has entered an exclusive distribution agreement for Israel with Dover Medical & Scientific Equipment Ltd. The agreement covers sales of all products in the Bactiguard Infection Protection portfolio. “Changing our market strategy for Israel from direct sales to sales via a distributor is a more cost efficient way of expanding...
Bactiguard delivers an order of some 20 000 products for infection control to Southern Africa, comprising both Foley and central venous catheters for the healthcare system in Angola. In July 2014, Bactiguard expanded its market presence to seven countries in Sub-Saharan Africa and made an initial delivery of Foley catheters to Zambia. The...
The annual general meeting of Bactiguard Holding AB (publ), (“Bactiguard”), will be held on Thursday, 21 May 2015 at 2:00 pm at Vasagatan 7 in Stockholm, in the Vasa Hall. Registration commences at 1:00pm and coffee will be served before the meeting. Shareholders right to participate and notification Shareholders wishing to participate at...
The annual report for Bactiguard Holding AB (publ) 2014 is now available at www.bactiguard.com The annual report is available in both a Swedish and English online version and as a downloadable PDF document. A printed version of the report will be available from 6 May and can be ordered at info@bactiguard.se. This is information that Bactiguard...
Bactiguard has terminated the distribution agreement for Russia and evaluates an alternative sales strategy for India. In connection with the above, the company has decided to make reservations in the interim results for the first quarter of 2015 for doubtful receivables, with a negative effect on results of approximately MSEK 24. During the...
Bactiguard expands in Europe by entering an exclusive distribution agreement for Switzerland, covering all products in the Bactiguard Infection Protection portfolio. “We are delighted about our expansion in Switzerland, a market recognized for its high quality healthcare. We have managed to break into one of Europe's toughest markets, which...
Fourth quarter (October-December 2014) Revenues amounted to SEK 25.1 (47.9) million EBITDA amounted to SEK -3.9 (25.2) million Reported net profit for the quarter amounted to SEK -15.7 (18.9) million, corresponding to SEK -0.47 (0.95) per share. Net profit for the quarter has been negatively affected by market valuation of the bond with SEK -1.1...
Bactiguard Holding AB publishes the year end report for 2014 on Thursday 19 November at 08:00 CET In connection with this, a conference call for analysts and media will be held at 10:00 CEO on February 19. CEO Johan Rugfelt and CFO Fredrik Järrsten will present the report and answer questions. The year end report will be available at...
The Board of Directors has appointed Niels Christiansen as the new CEO of Bactiguard. Niels Christiansen has extensive management experience from various positions in the medical device, life science and energy sectors, most recently as the CEO of HemoCue AB. He will assume his new position in Bactiguard on March 16. At that time, Johan Rugfelt...
